SK Biopharmaceuticals Submits New Epilepsy Drug Formulation to FDA as Market Watches Closely
On April 1, 2026, South Korean pharmaceutical company SK Biopharmaceuticals announced a significant step in expanding its epilepsy treatment portfolio. The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an oral suspension formulation of its epilepsy drug cenobamate, marketed in the U.S. As XCOPRI®. This move aims to improve treatment accessibility for patients who struggle with swallowing traditional tablets, particularly children and elderly individuals with partial-onset seizures (POS).
The submission comes at a time when SK Biopharmaceuticals’ stock performance has drawn attention from investors and market analysts. While the company’s shares closed with a modest gain on April 27, 2026, the broader market reaction has been cautious, reflecting both optimism about the drug’s potential and uncertainty about its commercial success. The oral suspension formulation, if approved, could address a critical unmet need in epilepsy care, offering a more flexible dosing option for patients with varying needs.
Epilepsy affects approximately 50 million people worldwide, according to the World Health Organization. Partial-onset seizures, the most common type of seizure in adults with epilepsy, can significantly impair quality of life. Current treatment options often involve tablets or capsules, which can be difficult for some patients to swallow, leading to inconsistent medication adherence. SK Biopharmaceuticals’ new formulation seeks to bridge this gap by providing a liquid alternative that maintains the drug’s efficacy while improving ease of use.
Cenobamate: A Breakthrough in Epilepsy Treatment
Cenobamate, the active ingredient in XCOPRI®, was first approved by the FDA in 2019 for the treatment of partial-onset seizures in adults. The drug has since gained recognition for its effectiveness in reducing seizure frequency, with clinical trials demonstrating significant improvements in patients who had previously struggled with uncontrolled seizures. The oral suspension formulation submitted to the FDA is designed to deliver the same therapeutic benefits as the tablet version but in a more adaptable form.
In a press release issued by SK Biopharmaceuticals, the company highlighted the results of a pharmacokinetic study presented at the 2025 American Epilepsy Society (AES) Annual Meeting. The study found that the oral suspension formulation exhibited similar absorption and drug exposure patterns to the tablet, confirming its pharmacokinetic equivalence. This data was a key component of the NDA submission, supporting the formulation’s potential as a viable alternative for patients.
Dong-hoon Lee, CEO of SK Biopharmaceuticals, emphasized the patient-centered approach behind the new formulation. “The oral suspension formulation reflects our commitment to addressing the real-world challenges faced by patients who have difficulty swallowing tablets,” Lee stated. “By expanding our treatment options, we aim to meet unmet medical needs and strengthen our global prescription base.”
Market Reaction and Investor Sentiment
Despite the promising clinical data and the potential market expansion, SK Biopharmaceuticals’ stock (KRX: 326030) has experienced mixed reactions from investors. On April 27, 2026, the company’s shares closed with a slight gain, but the overall market sentiment has been described as “watchful,” with investors adopting a wait-and-see approach. This cautious optimism is not uncommon in the pharmaceutical industry, where drug approvals and commercial launches can significantly impact stock performance.
The company’s existing portfolio includes not only cenobamate but also solriamfetol, a treatment for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. Solriamfetol, marketed as SUNOSI® in the U.S., received FDA approval in 2019 and has contributed to SK Biopharmaceuticals’ growing presence in the global pharmaceutical market. Although, the success of the oral suspension formulation for cenobamate could play a pivotal role in shaping the company’s future growth trajectory.
Analysts have noted that the oral suspension market for epilepsy drugs is relatively untapped, with few competitors offering similar formulations. If approved, XCOPRI® oral suspension could capture a significant share of the market, particularly among pediatric and geriatric patients. However, the FDA’s review process is rigorous, and the outcome remains uncertain until the agency completes its evaluation.
Addressing Unmet Needs in Epilepsy Care
Epilepsy is a complex neurological disorder that requires personalized treatment approaches. For many patients, finding the right medication and dosage can be a lengthy and challenging process. The introduction of an oral suspension formulation for cenobamate could simplify this process, particularly for patients who require precise dosing adjustments or have difficulty swallowing pills.
The oral suspension formulation is expected to be particularly beneficial for children with epilepsy, a population that often faces unique challenges in medication administration. SK Biopharmaceuticals is already conducting clinical trials to expand the use of cenobamate to pediatric patients, with the goal of obtaining FDA approval for younger age groups in the future. The company’s dual strategy—expanding the formulation options for adults while pursuing pediatric indications—reflects a comprehensive approach to addressing the diverse needs of epilepsy patients.
In addition to its clinical benefits, the oral suspension formulation could also improve medication adherence, a critical factor in managing epilepsy. Poor adherence to antiepileptic drugs is a common issue, often leading to breakthrough seizures and increased healthcare costs. By offering a more convenient and flexible dosing option, SK Biopharmaceuticals hopes to enhance patient compliance and, improve treatment outcomes.
What’s Next for SK Biopharmaceuticals and Cenobamate?
The FDA’s review of the NDA for the oral suspension formulation of cenobamate is expected to take several months. During this period, the agency will evaluate the clinical data, manufacturing processes, and labeling information to determine whether the drug meets the necessary safety and efficacy standards for approval. If approved, SK Biopharmaceuticals plans to launch the oral suspension formulation in the U.S. Market, with potential expansions to other regions in the future.
In the meantime, the company continues to advance its clinical development programs for cenobamate. Ongoing trials are exploring the drug’s potential in pediatric populations, as well as its use in combination with other antiepileptic medications. These efforts align with SK Biopharmaceuticals’ broader goal of establishing cenobamate as a cornerstone treatment for epilepsy, offering hope to patients who have not achieved adequate seizure control with existing therapies.
For investors and market observers, the coming months will be critical in assessing the commercial potential of the oral suspension formulation. While the initial stock market reaction has been cautious, a successful FDA approval could catalyze renewed interest in SK Biopharmaceuticals’ growth prospects. The company’s ability to execute its global expansion strategy, particularly in the U.S. And European markets, will be a key factor in determining its long-term success.
Key Takeaways
- FDA Submission: SK Biopharmaceuticals submitted an NDA for an oral suspension formulation of cenobamate (XCOPRI®) to the FDA on April 1, 2026, targeting adults with partial-onset seizures.
- Clinical Data: A pharmacokinetic study presented at the 2025 AES Annual Meeting confirmed that the oral suspension formulation is equivalent to the tablet version in terms of drug absorption and exposure.
- Market Potential: The oral suspension formulation could address unmet needs in epilepsy care, particularly for patients who struggle with swallowing tablets, including children and the elderly.
- Investor Sentiment: SK Biopharmaceuticals’ stock has shown modest gains but remains under watchful market scrutiny as investors await the FDA’s decision.
- Future Plans: The company is conducting clinical trials to expand cenobamate’s use to pediatric patients and exploring combination therapies for epilepsy.
Frequently Asked Questions
What is cenobamate?
Cenobamate is an antiepileptic drug approved for the treatment of partial-onset seizures in adults. It is marketed in the U.S. Under the brand name XCOPRI® and has shown effectiveness in reducing seizure frequency in clinical trials.
Why is the oral suspension formulation important?
The oral suspension formulation offers a more convenient dosing option for patients who have difficulty swallowing tablets, such as children, the elderly, and individuals with certain medical conditions. It also allows for more flexible dosing adjustments.
When will the FDA make a decision on the NDA?
The FDA’s review process typically takes several months. While an exact timeline has not been provided, a decision is expected in late 2026 or early 2027.
What are the potential benefits of cenobamate for pediatric patients?
SK Biopharmaceuticals is conducting clinical trials to evaluate cenobamate’s safety and efficacy in pediatric patients. If approved, the drug could provide a new treatment option for children with epilepsy, particularly those who do not respond well to existing therapies.
How does cenobamate compare to other epilepsy drugs?
Cenobamate has demonstrated significant efficacy in reducing seizure frequency in clinical trials, including in patients who had not achieved adequate control with other antiepileptic drugs. Its unique mechanism of action sets it apart from other medications in its class.
Conclusion
SK Biopharmaceuticals’ submission of the oral suspension formulation of cenobamate to the FDA marks a critical milestone in the company’s efforts to expand its epilepsy treatment portfolio. While the market reaction has been cautious, the potential approval of this new formulation could have far-reaching implications for patients and healthcare providers alike. As the FDA review process unfolds, stakeholders will be closely monitoring developments, with the hope that this innovation will bring much-needed relief to those living with epilepsy.
For the latest updates on cenobamate and SK Biopharmaceuticals’ clinical programs, readers can visit the company’s official website or follow the FDA’s drug approval announcements.
What are your thoughts on the potential impact of the oral suspension formulation for epilepsy patients? Share your views in the comments below and join the conversation on how medical innovations like this can improve patient care.